PharmAla To Supply Amsterdam UMC with LaNeo™ MDMA, Including Development of New Single-Capsule Stability Data

2026-02-23 - 13:43

TORONTO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeoTM MDMA and novel derivatives of MDMA (MDXX class molecules), announced that it has executed a binding supply agreement with Amsterdam University Medical Center (“Amsterdam UMC”) in the Netherlands for the provision of LaNeoTM 40mg MDMA capsules for use in a proposed clinical trial. Read More